Compare · GRDX vs NVO
GRDX vs NVO
Side-by-side comparison of GridAI Technologies Corp. (GRDX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRDX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 7442.0x GRDX ($29.0M).
- Over the past year, GRDX is up 88.8% and NVO is down 15.0% - GRDX leads by 103.8 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 2 for GRDX).
- NVO has more recent analyst coverage (25 ratings vs 0 for GRDX).
- Company
- GridAI Technologies Corp.
- Novo Nordisk A/S
- Price
- $3.89-2.99%
- $47.06-3.26%
- Market cap
- $29.0M
- $215.46B
- 1M return
- +32.76%
- -7.66%
- 1Y return
- +88.83%
- -14.96%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 2
- 9
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GRDX
- Amendment: SEC Form S-1/A filed by GridAI Technologies Corp.
- SEC Form 10-Q filed by GridAI Technologies Corp.
- Amendment: SEC Form S-1/A filed by GridAI Technologies Corp.
- GridAI Technologies Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form D filed by GridAI Technologies Corp.
- Amendment: SEC Form S-1/A filed by GridAI Technologies Corp.
- Amendment: GridAI Technologies Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
- GridAI Technologies Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Chief Executive Officer Sawyer Jason David was granted 500,000 shares, increasing direct ownership by 1,250% to 540,000 units (SEC Form 4)
- SEC Form POS AM filed by GridAI Technologies Corp.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S